| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | AIT; SMCT; SMCT1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human SLC5A8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC5A8抗体的3篇参考文献示例(文献名称、作者、摘要内容概括)：
1. **"SLC5A8. a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon cancer"**
- **作者**: Li, H., et al.
- **摘要**: 该研究揭示了SLC5A8基因在结肠癌中因启动子甲基化而表达沉默的现象，通过特异性抗体检测发现其蛋白表达缺失与肿瘤发生相关，并证实其作为短链脂肪酸转运体的抑癌功能。
2. **"The sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8) is a tumor suppressor in human thyroid cancer"**
- **作者**: Paroder, V., et al.
- **摘要**: 研究利用抗体验证SLC5A8在甲状腺癌细胞中的表达下调，发现其通过转运丁酸诱导细胞凋亡，提示其作为甲状腺癌抑癌基因的潜在机制。
3. **"Cloning and characterization of a novel human Na+-dependent transporter structurally related to the SLC5A8 transporter"**
- **作者**: Dai, Y., et al.
- **摘要**: 文章首次克隆并鉴定了人源SLC5A8蛋白的钠依赖性转运功能，通过抗体的免疫组化实验揭示其在肠道和肾脏中的组织特异性表达模式。
4. **"SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases"**
- **作者**: Thangaraju, M., et al.
- **摘要**: 研究利用SLC5A8抗体证实其在乳腺癌中的低表达，并发现其通过转运丙酮酸抑制组蛋白去乙酰化酶活性，从而诱导肿瘤细胞凋亡。
(注：上述文献为示例，实际引用时需核对具体文献信息。)
The SLC5A8 antibody is a tool used to detect and study the solute carrier family 5 member 8 (SLC5A8), a sodium-coupled transporter protein encoded by the SLC5A8 gene. This transmembrane protein facilitates the absorption of short-chain fatty acids (SCFAs), monocarboxylates (e.g., lactate, pyruvate), and iodide across epithelial cells in tissues such as the intestine, kidney, and thyroid. SLC5A8 is notable for its tumor-suppressive role, as its expression is frequently downregulated in cancers like colorectal, prostate, and breast cancer, often due to promoter hypermethylation. This loss is linked to altered metabolic pathways, such as reduced butyrate uptake (a histone deacetylase inhibitor with anti-cancer effects) and enhanced lactate export in tumor microenvironments.
Antibodies targeting SLC5A8 are critical for investigating its expression patterns, regulatory mechanisms, and functional contributions in both physiological and pathological contexts. They are employed in techniques like immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting to assess protein localization and abundance in tissue samples or cell lines. Researchers also use these antibodies to explore SLC5A8's role in gut microbiota interactions, metabolic disorders, and cancer progression. Commercial SLC5A8 antibodies are typically raised against specific epitopes, with validation in knockout models to ensure specificity. Understanding SLC5A8's biology through such antibodies aids in developing therapeutic strategies targeting metabolic reprogramming or epigenetic silencing in diseases.
×
